Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.
Earnings & Valuation
This table compares Lifecore Biomedical and Recordati Industria Chimica E Farmaceutica”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $128.87 million | 1.32 | -$40.50 million | ($1.07) | -4.20 |
| Recordati Industria Chimica E Farmaceutica | $2.96 billion | 4.04 | $501.92 million | $2.80 | 20.71 |
Insider & Institutional Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility & Risk
Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Recordati Industria Chimica E Farmaceutica has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.
Profitability
This table compares Lifecore Biomedical and Recordati Industria Chimica E Farmaceutica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -29.93% | N/A | -16.16% |
| Recordati Industria Chimica E Farmaceutica | 18.38% | 33.73% | 12.76% |
Analyst Ratings
This is a summary of current ratings and target prices for Lifecore Biomedical and Recordati Industria Chimica E Farmaceutica, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 1 | 1 | 1 | 0 | 2.00 |
| Recordati Industria Chimica E Farmaceutica | 0 | 1 | 0 | 1 | 3.00 |
Lifecore Biomedical presently has a consensus target price of $6.50, suggesting a potential upside of 44.77%. Given Lifecore Biomedical’s higher possible upside, equities research analysts plainly believe Lifecore Biomedical is more favorable than Recordati Industria Chimica E Farmaceutica.
Summary
Recordati Industria Chimica E Farmaceutica beats Lifecore Biomedical on 10 of the 15 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
About Recordati Industria Chimica E Farmaceutica
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
